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Abstract
Background: Overexpression of carbonic anhydrase (CA IX) is associated with poor survival in several adult-type
cancers but its expression is undocumented in Wilms tumour (WT), the most common tumour of the paediatric
kidney.
Methods: CA9 expression was measured using polymerase chain reaction (PCR) in 13 WTs and matched-paired
non-neoplastic kidneys (NKs). CA IX and hypoxia-inducible factor-1 a-subunit (HIF-1a) protein were quantified in 15
matched-paired WTs and NKs using enzyme-linked immunosorbent assays. CA IX and HIF-1a were localised by
immunostaining tissue sections of 70 WTs (untreated WTs, n = 22; chemotherapy-treated WTs, n = 40; relapsed/
metastatic WTs, n = 8). CA IX-positive untreated WTs (n = 14) were immunostained for vascular endothelial growth
factor (VEGF), glucose transporter-1 (GLUT1) and CD31. Double staining for CA IX and CD31 was performed in WTs
(n = 14).
Results: CA9 full length (FL) was significantly up-regulated in WTs compared to NKs (p = 0.009) by real-time PCR.
Conventional PCR showed expression of alternative splice variant in all NKs and WTs but FL in WTs only. WTs
showed a 2-fold increase in CA IX protein over NKs (p = 0.01). HIF-1a levels were up-regulated in WTs compared
to NKs, although the difference was not statistically significant (p = 0.09). CA IX and HIF-1a immunolocalisation
were observed in 63% and 93% of WTs, respectively. The median fraction of cells staining positively for CA IX and
HIF-1a was 5% and 22%, respectively. There was no significant association between the expression of either CA IX
or HIF-1a and clinicopathological variables in WTs resected following chemotherapy. VEGF and GLUT1
immunoreactivity was seen in 94% and 100% with the median fraction of 10% and 60% respectively. Co-expression
and co-localisation of all four hypoxia markers was seen in 7/14 and 6/14 cases respectively. CA IX was seen in well
vascularised areas as well as in the peri-necrotic areas.
Conclusions: Carbonic anhydrase 9 (mRNA and protein), and HIF-1a protein are overexpressed in a significant
portion of WTs. No significant association was detected between the expression of either CA IX or HIF-1a and
clinicopathological variables in WTs resected following chemotherapy. Cellular localisation studies in untreated WTs
suggest that CA IX and HIF-1a are regulated by hypoxia and non-hypoxia mechanisms.
Background
Wilms tumour (WT) is the most common paediatric
renal tumour, with an incidence of 1:10,000 children.
Although the prognosis of children with favourable clin-
ical and pathological factors is good, children with high-
risk, drug-resistant or metastatic disease have a mortal-
ity rate of 10-15%. Alternative therapeutic strategies are
therefore essential to improve the outcomes of the chil-
dren in this group.
Tissue hypoxia contributes to the progression and
chemoresistance of many human cancers by inducing
the up-regulation of genes associated with angiogenesis,
metabolism, cell survival and apoptosis [1]. The cellular
response to hypoxia is mediated by a key gene, hypoxia-
inducible transcription factor-1 a-subunit (HIF-1a), via
hypoxia response elements in the promoter regions of
target genes, which include carbonic anhydrase IX
(CA9) and vascular endothelial growth factor (VEGF)[1].
CA IX, a membrane glycoprotein, plays an important
role in the growth and survival of tumour cells under
both normoxic and hypoxic conditions [2,3]. Although
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activation, the amplitude of the response can be modu-
lated in normoxia by growth factors, oncogenes and
cytokines [4].
Up-regulation of HIF-1a and CA IX is observed in a
variety of epithelial cancers and correlates with poor
survival [1,5]. Epithelial cancers typically occur in adults
and only rarely occur in children. In contrast, solid
tumours (such as WTs) that occur in children are devel-
opmental disorders presenting different biological char-
acteristics [6]. In a study consisting of 18 WT samples,
HIF-1a and VEGF expression was detected in all WTs
using immunohistochemistry [7]. In a recent study, up-
regulation of CA9 in WTs was associated with high-risk
histology and was significantly correlated with metas-
tases [8]. The existence of two variants of CA9,f u l l
length (FL) and alternate spliced variant (ASV), has
been described in both hypoxic and non-hypoxic condi-
tions [9,10]. The ASV mRNA, which lacks the exons 8-
9, competes with FL in regulating extracellular pH in
mildly hypoxic conditions. ASV is expressed in both
normal and diseased tissues, while FL mRNA is upregu-
lated in non-small cell lung cancer and its expression
associated with poor prognosis [10]. Wittmann et al
used primers that did not distinguish between the two
isoforms of CA9 [8].
As CA IX is an attractive target for anti-cancer ther-
apy for several reasons, overexpression of CA9 [8] is an
important finding that is likely to be clinically relevant
[11,12]. Although changes in protein expression are
more likely to have a direct impact on biological beha-
viour than changes in transcriptional regulation or
mRNA expression, there is no information about CA IX
expression in WTs. The aims of this study were as fol-
lows: 1) to perform a comprehensive expression analysis
of carbonic anhydrase at mRNA (FL and ASV CA9)a n d
protein levels and HIF-1a protein in matched-paired
WTs and non-neoplastic kidneys (NKs), precursor
lesions (nephrogenic rests) [13], and fetal kidneys; (2) to
look for associations between the expression of either
CA IX or HIF-1a and clinicopathological features; and
(3) to compare the expression of CA IX with other
hypoxia markers and vascularity.
Methods
Tissue samples
The study was approved by the South Bristol and
North Somerset Research Ethics Committee (09/
H0106/4). The clinicopathological information, includ-
ing the size, weight, histological type, stage and risk
group, of 70 WTs was extracted from pathology
reports. All samples were obtained from the Paediatric
Pathology files of the University Hospitals Bristol NHS
Foundation Trust.
The tissue specimens were taken from 62 primary and
8 metastatic/relapsed WTs. The primary WTs were
obtained from patients undergoing nephrectomies with-
out chemotherapy (n = 22) and nephrectomies that
were performed after standard chemotherapy (n = 40)
according to the appropriate United Kingdom Wilms
tumour and Société Internationale d’Oncologie Pédiatri-
que protocols (reviewed by [14]). The metastatic sites
included lymph nodes (n = 2), the liver (n =2 )a n d
lungs (n = 4). Three WTs demonstrated focal anaplasia
(intermediate risk) and three demonstrated diffuse ana-
plasia (high-risk).
Areas of necrosis in 19/22 untreated WTs were
included for immunohistochemical (IHC) staining
because markers of perinecrotic localisation have been
studied in several cancers to elucidate their regulation
under hypoxic conditions in animals [15] and humans
[16-19]. 40 blocks from post-chemotherapy nephrect-
omy specimens were selected as anti-CA IX and/or
HIF-1a therapies [20] are likely to be used in this clini-
cal setting. Selected blocks contained representative
areas of the WT and adjacent non-neoplastic kidney for
comparison. A total of 26 nephrogenic rests were
included in the study. Sections from 5 fetal kidneys ran-
ging from 12- to 30-weeks’ gestation were also exam-
ined by IHC. Frozen tissue with at least 70% viable
tumour was available from 15 post-chemotherapy WTs.
Frozen tissue from 15 matched-paired NKs were also
available.
RNA extraction
Total RNA was extracted from 26 samples (13 WTs and
13 matched-paired NKs). RNA was extracted using TRI-
zol according to the manufacturer’s protocol (Invitrogen,
Paisley, Scotland, UK) and quantified on a NanoDrop
ND-1000 Spectrophotometer (Thermo Fisher Scientific,
Loughborough, UK).
Reverse transcription polymerase chain reaction
10 μg of RNA was reverse transcribed using the qScript
reverse transcription kit (Primerdesign, Southampton,
UK) as per manufacturer’sp r o t o c o l .T h ep r e s e n c eo f
CA9 isoforms in our samples was evaluated using two
sets of primers as previously described by Barathova et
al [9]. The FL isoform was identified using the h7S-h8A
primer set while the h7S-h10/7A set was used to detect
the ASV. cDNA was amplified for all PCR reactions in a
final volume of 25 μl containing PCR Master mix 5×
( P r o m e g a ,S o u t h a m p t o n ,U K ) ,1μM each of forward
and reverse primers at the following conditions: 10 min
at 95°C, 30 s at 95°C, 30 s at 62°C and 30 s at 72°C for
35 cycles and a final extension at 72°C for 7 min for FL
primers. Annealing for the ASV primers was performed
at 54°C for 30 s. Normal stomach which contains both
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were resolved by electrophoresis on a 2.5% ethidium
bromide stained Agarose Micro Plus gel (alpha labora-
tories, Eastleigh, UK). After visualisation, amplicons
were extracted from the gel according to the instruc-
tions of the Qiagen Gel Extraction kit (Qiagen, Crawley,
UK). 20% of the products were then sequenced to con-
firm their identity and localise the splicing site.
Real-time quantitative polymerase chain reaction
RNA quality analysis was performed using the Bio-Rad
Experion System (Bio-Rad Labs, Hemel Hempstead,
UK). Universal mRNA (AMS Biotechnology, Abingdon,
UK) served as the positive control. No reverse transcrip-
tase and no template served as the negative controls. A
total of 1 μg of RNA was used for each RT reaction in a
final volume of 20 μl using the iScript cDNA Synthesis
kit and cycling conditions specified by the manufacturer
(Bio-Rad Labs, Hemel Hempstead, UK). Real-time quan-
titative polymerase chain reaction (q-PCR) for CA9 was
performed using a Roche LightCycler 480 (Roche Diag-
nostics Gmbh, Mannheim, Germany). The cDNA was
analysed by q-PCR using the LC480 probe mastermix
(Roche Diagnostics Limited, West Sussex, UK) and
detected on the FAM channel. The sequences of the
sense and antisense PerfectProbe (Primerdesign, South-
ampton, UK) for FL (accession number: NM_001216)
were 5’-GCTCCACACCCTCTCTGAC-3’ and 5’-
CTCAATCACTCGCCCATTCAA-3’, respectively. The
size of the amplicons was 97 bp. The amplification con-
ditions consisted of an initial denaturation step of 95°C
for 10 min, followed by 50 cycles of denaturation at 95°
C for 15 s, annealing at 50°C for 30 s and extension at
72°C for 15 s.
Relative expression of the transcripts was quantified
after normalising the levels with the geometric mean of
three endogenous reference genes, PPIA, GUS and TBP.
These genes were found to have the least variation
among 12 reference genes (the TATAA human endo-
genous control gene panel, Göteborg, Sweden) in a pre-
liminary experiment. Data analysis was performed using
GenEx 5.0 (MultiD, Göteborg, Sweden), which uses the
ΔΔCt relative quantification model with PCR efficiency
correction and reference gene normalisation.
Protein extraction
Total protein was extracted from 15 WTs and 15
matched-paired NKs. Snap-frozen tissue samples were
homogenised in ice-cold lysis buffer composed of 1%
Triton X-100 buffer containing 1:100 dilutions of pro-
tease and phosphatase inhibitor cocktails (Sigma-
Aldrich, Dorset, UK). After homogenisation, the samples
were centrifuged at 12,000 × g for 15 min at 4°C. Total
protein was quantified using the Bradford assay
following the manufacturer’s instructions (Sigma-
Aldrich, Dorset, UK).
Western blotting
A total of 40 μg/sample of protein was denatured by
boiling at 100°C in Laemmli buffer for 5 min, separated
using a 12% SDS-PAGE gel (NuPage Novex Bis-Tris
mini gels, Invitrogen, Paisley, Scotland, UK) and trans-
ferred onto polyvinylidene fluoride (PVDF) membrane
(Immobilon membranes, Millipore, Watford, UK). CA
IX and HIF-1a were detected by immunoblotting using
mouse anti-CA IX (1:50, M75) and mouse anti-HIF-1a
(1:500, clone ESEE122, Abcam, Cambridge, UK) for 2 h.
After washing with PBS-Tween (0.05%), the membranes
were incubated with horseradish peroxidase-conjugated
goat anti-mouse IgG at 1:5000 (Thermo Fisher Scienti-
fic, Loughborough, UK) for 2 h at RT. Immunodetection
of the protein was performed using an enhanced chemi-
luminescence (ECL) kit following the manufacturer’s
instructions (Immobilon Western Chemiluminescent
HRP Substrate, Millipore, Watford, UK). Immunoreac-
tive bands were visualised on Hyperfilm ECL (GE
Healthcare, Chalfont St. Giles, Bucks, UK), and the pre-
dicted protein was confirmed by recombinant CA IX
and HIF-1a that was run alongside the samples. To
control for protein loading, the membranes were
stripped and re-probed with anti-GAPDH (1:5000,
AF5718, R&D Systems, Abingdon, UK).
Enzyme-linked immunosorbent assay (ELISA)
CA IX and HIF-1a concentrations were measured in
WT and matched-paired NK samples using the human
CA IX Duoset and HIF-1a Duoset IC enzyme-linked
immunosorbent assay kits (DY2188 and DYC1935-5,
respectively, R&D Systems, Abingdon, UK), according to
the manufacturer’s instructions. Standard curves were
constructed using 2-fold serial dilutions of recombinant
CA IX (range 0 - 2000 pg/ml) and HIF-1a (range 0 -
8000 pg/ml). Optical densities were determined using a
spectrophotometer at l = 450 nm with corrective read-
ing at l = 570 nm. Each protein extract was measured
three times, and the tests were performed in triplicate
each time. Both the intra-assay and inter-assay variation
were < 10%.
Immunohistochemical techniques
4 μm thick conventional (whole) sections of formalin-
fixed paraffin-embedded tissues were stained using a
BOND-III automated immunostainer (Leica Biosystems,
Milton Keynes, UK). Anti-CA IX (1:50), anti-HIF-1a
(1:2500), mouse anti-VEGF (1:300, VG1, Abcam, Cam-
bridge, UK), and rabbit anti-GLUT1 (1:800, AB1340,
Merck Millipore, Watford, UK) were applied to the sec-
tions for 1.5 h. The Bond™ Polymer Refine Detection
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was used. Normal appendix tissue was used as a positive
control for CA IX, breast carcinoma tissue served as a
control for HIF-1a, VEGF and GLUT1. Using the same
concentration as the primary antibodies, non-immune
isotype IgG was used as a negative control.
To study the precise relationship between CA IX and
vascularity, double immunostaining was performed on 14
pre-chemotherapy WT samples that showed necrosis and
for which unstained sections were available. To achieve
this, CA IX and mouse anti-CD31 (1:100, M0823, Leica
Novocastra, Milton Keynes, UK) antibodies were incubated
for 2 h and 4 h followed by detection using the Bond™
Polymer Refine Detection system and Bond™ Polymer
Refine Red Detection system (DS9800 and DS9390, Leica
Novocastra, Milton Keynes, UK) respectively.
The percentage of cells expressing CA IX, HIF-1a,
VEGF and GLUT1 was recorded in each of the three
WT components: blastema, epithelium and stroma.
Weak or focal staining in < 1% of the sections was con-
sidered negative. Positive nuclear or cytoplasmic HIF-1a
staining was graded by the intensity (weak, moderate or
strong), all of which were considered positive. Because
CA IX, VEGF and GLUT1 staining was of uniformly
strong intensity in all three WT components, the per-
centage of cells stained for each element was recorded,
but the intensity was not scored.
Statistical analyses
The means of the duplicate mRNA expression profile data
were used for analysis. Relative expression levels from the
PCR were positively skewed; therefore, they were logarith-
mically transformed prior to statistical analysis and geo-
metric means (CIs) used for data summary. The (log-
transformed) expression values of paired NK and WT
samples were compared using paired Student’st - t e s t s .
For the immunohistochemical scores, chi-squared tests
were used to compare groups exhibiting any positive
staining. Yates’ continuity correction was used for 2 × 2
tables. Fisher’s Exact tests (two-tailed) were used where
expected frequencies were small.
For the ELISA comparisons, averages of triplicate
measurements were used, again after logarithmic trans-
formation to remove positive skewness. Paired Student’s
t-tests were used to compare the expression in 1:1
paired normal and WT samples. Mixed effects regres-
sion models were used to explore the relationship
between CA IX and HIF-1a. A 5% level of significance
was used throughout the analyses.
Results
CA9 isoforms are expressed in WT and NK
On qualitative PCR analyses, CA9 FL was detected only
in WTs while the ASV isoform was detected in all the
samples (Figure 1a upper panel and lower panel, respec-
tively). On sequencing the recovered PCR products, the
expected sequences were obtained.
CA9 expression is significantly up-regulated in WTs
Using quantitative PCR, there was significant up-regula-
tion of CA9 FL in 13 matched-paired WTs and NKs
(Figure 1b, p = 0.009 using log-transformed values). The
mean of the relative expression in the paired samples
was 2.87 [median, 2.89; SE, 0.31] in the WTs and 1.85
[median, 1.84; SE, 0.19] in the NK samples, indicating a
1.55-fold higher expression in the former.
CA IX and HIF-1a are expressed in WTs
In preliminary experiments, we performed western blot-
ting to confirm the expression and specificity of the anti-
bodies used in our laboratory (Figure 2). HIF-1a (Figure
2 upper panel) was expressed in WTs and NKs. Transla-
tion of CA9 into CA IX was evidenced by the characteris-
tic twin bands at 54 and 58 kDa (Figure 2 middle panel).
CA IX and HIF-1a immunolocalisation in WTs,
nephrogenic rests (NRs), fetal kidneys and non-neoplastic
kidneys (NKs)
Immunolocalisation studies were performed in all 70
WTs to examine the distribution of hypoxia markers.
Figure 1 a) RT-PCR analysis of CA9 isoforms in paired non-
tumoral kidneys (NK) and Wilms tumours (WTs). Upper panel:
CA9 full length (FL), (154 bp using primers h7S-8A), Lower panel:
CA9 alternative splice variant (ASV) (140 bp using primers h7S-h10/
7A). Stomach (S) was used as a positive control for both FL and ASV
CA9. No test control (NTC). b) The mean relative expression of CA9
FL in 13 matched-paired NK and WTs. Total RNA was extracted from
NK and WT samples. Each data point indicates log-transformed
relative mRNA expression levels normalised to the lowest
expression. CA9 FL expression was significantly higher in WTs than
in NKs (p = 0.009). MW = molecular weight marker.
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including the proportions of the individual cellular com-
ponents, is presented in Table 1.
CA IX: 44/70 (63%) WTs expressed CA IX. Strong
membranous/cytoplasmic immunoreactivity was
detected in at least one of the three WT components
(Figures 3a, 3e), whereas NRs, NKs and fetal kidneys
were essentially negative.
HIF-1a: 65/70 (93%) WTs expressed HIF-1a. Two pat-
terns of immunostaining were observed in the blastemal
and epithelial components, nuclear and cytoplasmic.
Nuclear expression of moderate to strong intensity was
observed mainly in the perinecrotic areas (Figure 3b, h),
whereas cytoplasmic staining was more diffusely distribu-
ted and generally demonstrated weak intensity (Figure 3f).
The staining of fetal kidneys revealed weak, diffuse
immunoreactivity in the metanephric blastema, tubules
and glomerular podocytes but no stromal expression
was seen. All the NKs showed HIF-1a immunoreactivity
located predominantly in the tubules and collecting
ducts. Occasional glomerular podocyte staining was also
observed. Tubular staining of variable intensity in the
cytoplasm was observed in 20 of 26 nephrogenic rests,
ranging from weak to moderate in intensity.
Relationship of CA IX with hypoxia markers
Untreated WTs (n = 22) were immunostained to avoid
bias due to direct toxic effects of drugs in WTs resected
following chemotherapy. To study the relationship of
CA IX, HIF-1a,G L U T 1a n dV E G Fw i t hh y p o x i a ,1 4
WTs containing areas of necrosis were assessed. The
results are summarised in Table 2. Perinecrotic coex-
pression of all four markers was seen in 7/14 (50%)
while colocalisation of all four was seen in 6/14 (43%)
(Figures.3a-d).
Relationship of CA IX with vascularity
Of the 14 WT samples that were double stained, all
showed perinecrotic CA IX upregulation away from
CD31 stained vessels (Figure 4a). 3/14 (22%) showed CA
IX expression adjacent to CD31 stained vessels (Figure
4b).
CA IX and HIF-1a levels are higher in WTs than in
matched NKs
B e c a u s eI H Ci sas u b j e c t i v ea n ds e m i - q u a n t i t a t i v et e c h -
nique, CA IX and HIF-1a levels were quantified in the
protein extracts of 15 WT and matched-paired NK sam-
ples using sensitive ELISAs (Figure 5a, b). The geo-
metric mean of the CA IX levels was 0.09 pg/μg protein
[95% CI: 0.06-0.13] in NKs and 0.20 pg/μg[ 9 5 %C I :
0.13-0.31] in WTs. Compared to the matched-paired
NKs, CA IX levels were significantly higher in WTs (p =
0.012, paired t-test using log-transformed values).
The geometric mean of the HIF-1a levels was 1.56 pg/
μg total protein [95% CI: 0.96-2.52] in NKs and 2.49 pg/
μg [95% CI: 1.62-3.81] in WTs. The difference, however,
was not statistically significant (p =0 . 0 9 3 ,p a i r e dt - t e s t
using log-transformed values). The trend indicating
increased CA IX protein levels together with increased
HIF-1a levels in WTs compared to NKs is illustrated in
Figure 6a, which links the paired NK and WT samples.
CA IX and HIF-1a correlation
After log transforming the NK sample data, CA IX
expression demonstrated a strong positive correlation
with HIF-1a [r = 0.82, 95%CI: 0.52-0.94, p < 0.001]. The
estimated regression slope for CA IX on HIF-1a was
0.63 [95%CI: 0.36-0.89]. As depicted in Figure 6b, which
provides separate regression lines for the NK and WT
samples fitted using mixed model regression, the
Figure 2 Protein expression in cell lysates from matched-
paired NK and WT samples as detected by western blot
analysis. Figure 2a. HIF-1a (upper panel) and CA IX (middle panel)
and the lower panel indicates even protein loading as evidenced by
detection of the GAPDH control from the same extract. GAPDH is
visible as a band of approximately 38 kDa. Upper panel: A single
band at 120 kDa indicates full length HIF-1a protein detected in
two post-CT samples (pairs 1 and 3). HIF-1a is higher in WTs than in
matched-paired NKs. Middle panel: CA IX expression, indicated by
two bands of 54 kDa and 58 kDa, is higher in two out of three WTs
compared to their corresponding NKs.
Table 1 Immunolocalisation of CA IX and HIF1-a in WTs (n = 70)
%WT stained Median %
of all cells stained (range)
Blastema % Epithelium % Stroma % Anaplastic
cells %
CA IX 63 5 (0-40) 5 10 15 0
HIF1-a 93 22 (0-75) 24 28 1 0
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Figure 3 Immunohistochemical staining for CA IX (a, e, g), HIF-1a (b, f, h), GLUT1 (c) and VEGF (d) in WTs. Co-localisation of CA IX, HIF-
1a, GLUT1 and VEGF in perinecrotic blastema (a-d). Perinecrotic tubules show CA IX but not HIF-1a expression (e, f). Perinecrotic blastemal cells
are negative for CA IX, but nuclear expression of HIF-1a is present (g, h).
Dungwa et al. BMC Cancer 2011, 11:390
http://www.biomedcentral.com/1471-2407/11/390
Page 6 of 10relationship among the WT samples was weaker; how-
ever, the slopes did not differ significantly (p = 0.052).
Relationship between CA IX and HIF-1a cellular
expression and clinicopathological variables in WTs
No significant difference in either CA IX or HIF-1a
expression was detected between primary and relapse/
metastatic WTs (Table 3). Similarly, there was no signif-
icant association between CA IX or HIF-1a cellular
expression and the other variables, including histological
type, stage, risk-group, size of WTs and kidney weight.
Additionally, no significant difference was detected in
either CA IX or HIF-1a cellular expression in pre-che-
motherapy versus post-chemotherapy WT samples.
Discussion
This study is the first to assess the cellular distribution
of CA IX protein and quantify it in Wilms tumours
(WTs). The main strengths of our study include the use
of a wide range of techniques for expression analysis
and the comparison between WTs and matched-paired
NKs to reduce the confounding variation inherent in
biological samples. Our study clearly demonstrates that
a) CA IX is over-expressed in up to 63% of WTs at the
cellular level and b) CA9 FL and CA IX levels are signif-
icantly increased in WTs compared with NKs. We also
demonstrate that HIF-1a protein is up-regulated in
WTs compared to NKs. The present study also demon-
strates the co-expression of CA IX with other hypoxia
markers such as VEGF and GLUT1 in addition to HIF-1
a. The presence of CA IX in well vascularised areas, as
shown by double staining of CD31 with CA IX suggests
that CA IX is regulated by other factors other than
hypoxia.
By using the M75 antibody, which recognises the
extracellular proteoglycan-like domain of CA IX and is
considered the gold standard in immunohistochemical
CA IX detection, CA IX was detected in all three WT
components. In our samples, the stained tumour frac-
tion was 5%, an observation in agreement with the low
frequencies previously described by others [19,21]. Gen-
erally, the method used to establish the prognostic sig-
nificance of HIF-1a and CA IX expression in other
tumours is immunohistochemistry [1,5]. Intratumoral
heterogeneity, however, is a feature of CA IX cellular
detection that is emphasised by this study and has been
reported for other tumours [21,22]. In a seminal study
of 110 previously treated cervical cancers, measurement
of CA IX in multiple biopsies indicated that intratu-
moral heterogeneity accounted for 41% of the total var-
iance in the data set [21]. We used conventional, whole
tissue sections to reduce the inherent sampling error
Table 2 HIF-1a, CA IX, GLUT1 and VEGF expression in pre-chemotherapy WTs
Marker Tumours +ve (%) Level of expression (median) Pattern of co-expression
CA IX 56 0-60 (5) + + + + - - - - + + - - + - +
HIF-1a 94 0-80 (40) + + + - + - - - + - + + - + -
GLUT1 100 30-80 (60) + + - + + + - - - - + - + - -
VEGF 94 5-90 (10) + - + + + + + - - - - - - + +
Co-expression
a 710150000000000
Co-localization
b 610040000010000
Table shows expression in pre-chemotherapy WT samples that were CA IX positive (n = 14).
a number of positive cases showing specific staining of all four markers (+ or - sign in each line indicates positivity and negativity in respective staining in the
same tumour)
b number of positive cases showing specific staining of all four markers (+ or - sign in each line indicates positivity and negativity in respective staining in the
same area of the same tumour)
N
B
CA IX/CD31
a
CA IX/CD31
b
B
Figure 4 Perinecrotic staining of CA IX (brown) away from
CD31-stained vessels in red (a). Membranous CA IX staining
(brown) of tubules adjacent to blood vessels highlighted by CD31
staining (red) (b). N = necrosis; B = blastema.
Figure 5 CA IX and HIF-1a protein levels in total cell lysates of
15 Wilms tumours (WTs) and 15 matched-paired uninvolved
kidney (NK) samples as quantified by ELISA.a )C AI Xi s
significantly higher in WTs. b) HIF-1a is up-regulated in WTs
compared to paired NKs. Paired results are plotted on a log scale.
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and in small biopsies. We were unable to detect a signif-
icant association with clinicopathological variables,
including metastatic status. A possible explanation for
the lack of association is that there were too few
samples in some subgroups to effectively evaluate the
relationship between CA IX expression and these
variables.
We showed CA9 ASV expression using qualitative
PCR in all NKs and WTs in keeping with previously
published data, [9,10]. We also showed an increase in
CA9 FL in WTs compared to NKs using quantitative
PCR. Our results are in line with increased CA9 FL
expression shown in non-small cell lung cancer samples
[10]. As CA9 FL was not expressed or expressed in very
low amounts in normal kidneys, our study also indicates
that it is a tumour-associated gene, which is an impor-
tant finding because the other genes detected in WTs
and nephrogenic rests are usually expressed during
organogenesis [13]. The precise role of CA IX in WTs,
however, remains to be elucidated. A recent study
demonstrated that hypoxia down-regulates several genes
involved in maintaining cell-cell interactions, including
E-cadherin, which promotes epithelial to mesenchymal
transition and invasion [23]. The proteoglycan-like
region at the N-terminus of CA IX is implicated in cell
Figure 6 Relationship between CA IX and HIF-1a protein levels
in cell lysates of 15 Wilms tumours (WT) and 15 matched-
paired uninvolved kidney (NK) samples as quantified by ELISA.
Open and closed circles indicate NK and WT samples, respectively.
a) Pairs of results from the same patient are linked. b) Regression
lines fitted to the NK (continuous line) and WT (dotted line) samples
using a mixed regression model.
Table 3 Relationships between CAIX and HIF-1a & clinicopathological variables
Characteristic No No (%) stained for CAIX p-value No (%) stained for HIF-1a p-value
Relapse/metastases
Present 8 4 > 0.99 6 0.49
Absent 62 40 (65%) 59 (95%)
Chemotherapy status
Pre-CT 22 16 (73%) 0.47 20 (91%) 0.29
Post-CT 40 24 (60%) 39 (98%)
Stage Post-CT
1 14 9 (64%) 0.85 14 (100%) †
2 13 7 (54%) 13 (100%)
3/4/5 13 8 (62%) 12 (92%)
Risk group Post-CT
High-risk 5 2 0.37 5 > 0.99
Low/Intermediate risk 35 22 (63%) 34 (97%)
Histological type Post-CT
Blastemal 8 3 † 8 †
Epithelial/Stromal 10 9 (90%) 10 (100%)
Mixed 16 8 (50%) 15 (94%)
Regressive 6 4 6
*Size (cm) Post-CT > 0.99 0.45
≤9 22 13 (59%) 22 (100%)
> 9 18 11 (61%) 17 (94%)
**Weight (g) Post-CT
≤299 20 7 (35%) 0.057 17 (85%) > 0.99
> 299 20 14 (70%) 17 (85%)
CT - chemotherapy, * size - 9 cm is the median size, **weight - 299 g is the median weight of total nephrectomy specimens. In 3 cases weight was unavailable,
while 2 were partial nephrectomies.
†expected frequencies too small to do c
2-test
8 WT samples obtained from metastatic sites in addition to their primary tumours. Repeated samples from the same patient were regarded as independent
samples in these comparisons.
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Page 8 of 10adhesion [24,25], and CA IX’s distribution overlaps with
that of E-cadherin in canine kidney epithelial cells in
vitro [26]. Furthermore, CA IX co-precipitates with b-
catenin, reduces the binding of E-cadherin to b-catenin
and thereby destabilises intercellular adhesion [26].
Importantly, E-cadherin expression is not only decreased
in WT [27-29] but is also associated with advanced-
stage disease [30]. Thus, it is possible that CA IX desta-
bilises E-cadherin’s linkage to the cytoskeleton, resulting
in decreased cell-cell adhesion and contributing to WT
invasion.
The cellular overlap between HIF-1a and CA IX in
perinecrotic regions indicates that both are regulated by
hypoxia in WTs. The localisation of CA IX in areas of
tumour necrosis is of particular interest in terms of
hypoxia regulation [15-19,31]. HIF-1a is the key tran-
scriptional regulator of CA IX, and both co-localise in
many embryonic and fetal tissues. A lack of co-expres-
sion in other tissues, however, indicates that CA IX is
only partially regulated by HIF-1a expression. For exam-
ple, HIF-1a,b u tn o tC AI X ,i se x p r e s s e di nt h eh u m a n
fetal and adult kidney as detected by immunohistochem-
istry [32,33]. Although a predominant perinecrotic pat-
tern was observed in our study, CA IX was also present
in areas distant from necrosis. This partial correlation is
likely due to differences in the kinetics of HIF-1a and
CA IX. HIF-1a is rapidly induced and degraded within
minutes of re-oxygenation, whereas CA IX, induced
hours later, is relatively stable and has a half-life of 2-3
days [34].
HIF-1a and CA IX expression in perivascular areas is
in agreement with their regulation by hypoxia-indepen-
dent-pathways in WT and in line with previous studies
of epithelial cancers [15-19,31]. Mild hypoxia gener-
ated in high-density cultures can also increase HIF-1a
synthesis and CA IX expression via the phosphatidyli-
nositol 3-kinase (PI-3K) pathway [35]. Extracellular
acidosis, a common feature in tumours, increases HIF-
1a protein accumulation and CA9 transcriptional
activity under normoxic conditions [36]. Additionally,
growth factors, such as transforming growth factor-a
(TGF-a), can also increase CA IX expression by
increasing HIF-1a synthesis [35] via both the PI-3K
and mitogen-activated protein kinase pathways [4]. In
contrast to regulation under hypoxic conditions, which
affects all cells by stabilising HIF-1a protein and
increasing HIF-1 transactivation function, this regula-
tion is cell-type specific and works mainly by increas-
ing HIF-1a synthesis [4]. Although neither activating
mutations [37] nor the amplification of EGFR [38]
have been detected, increased TGF-a and EGFR
expression is observed in WTs at both the mRNA [8]
and histological levels [39].
Conclusions
Our expression data clearly demonstrate that carbonic
anhydrase (mRNA and protein) is up-regulated in
untreated and treated WTs as compared with normal
kidneys and WT precursor lesions (nephrogenic rests).
We did not detect significant associations between
either CA IX or HIF-1a protein and clinicopathological
variables, including metastatic status in post-chemother-
apy-treated WTs. Cellular localisation studies in
untreated WTs suggest that CA IX and HIF-1a are
regulated by hypoxia and non-hypoxia mechanisms.
Abbreviations
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